AJP - Endocrinology and Metabolism, Vol 272, Issue 5 E723-E736, Copyright © 1997 by American Physiological Society

ARTICLES

Renal assimilation of oligopeptides: physiological mechanisms and metabolic importance

S. A. Adibi
Clinical Nutrition Research Unit, University of Pittsburgh School of Medicine, Pennsylvania 15213, USA.

Assimilation of systemic oligopeptides (di- and tripeptides) is largely a function of kidneys. The most specific and unique mechanism utilized for the performance of this renal function is transport, followed by intracellular hydrolysis and then release of constituent amino acids to the systemic circulation. Among tissues examined (liver, kidney, intestine, and muscle), kidney is the only tissue capable of accumulating dipeptides in concentrations that are greater than their plasma concentrations. Kidney also is the tissue with the highest cytoplasmic dipeptidase activity. Intracellular accumulation is mediated by two transporters (Pept-1 and Pept-2), both of which have been recently cloned. These transporters use dipeptides and tripeptides as substrates and rely on protons and membrane potential for their driving force. Pept-1 is a low-affinity, high-capacity transporter, and Pept-2 is a high-affinity, low-capacity transporter. The nutritional and metabolic regulation of renal assimilation of oligopeptides is suggested by the selective decrease in dipeptide balance across the kidneys of starved human subjects and by the insulin stimulation of dipeptide transport by a renal cell line. Peptiduria has been observed in a variety of diseases, but the mechanism, except in genetic diseases affecting hydrolysis of oligopeptides, is not known. Finally, the capacity for active transport of oligopeptides and peptidomimetic drugs enables kidneys to play major roles in nutritional and pharmacological therapies.

This article has been cited by other articles:

				I. M. Frey, I. Rubio-Aliaga, A. Siewert, D. Sailer, A. Drobyshev, J. Beckers, M. H. de Angelis, J. Aubert, A. B. Hen, O. Fiehn, et al. Profiling at mRNA, protein, and metabolite levels reveals alterations in renal amino acid handling and glutathione metabolism in kidney tissue of Pept2-/- mice Physiol Genomics, February 12, 2007; 28(3): 301 - 310. [Abstract] [Full Text] [PDF]

				P. G. Boelens, P. A. M. van Leeuwen, C. H. C. Dejong, and N. E. P. Deutz Intestinal renal metabolism of L-citrulline and L-arginine following enteral or parenteral infusion of L-alanyl-L-[2,15N]glutamine or L-[2,15N]glutamine in mice Am J Physiol Gastrointest Liver Physiol, October 1, 2005; 289(4): G679 - G685. [Abstract] [Full Text] [PDF]

				H. Daniel and I. Rubio-Aliaga An update on renal peptide transporters Am J Physiol Renal Physiol, May 1, 2003; 284(5): F885 - F892. [Abstract] [Full Text] [PDF]

				A. Gangopadhyay, M. Thamotharan, and S. A. Adibi Regulation of oligopeptide transporter (Pept-1) in experimental diabetes Am J Physiol Gastrointest Liver Physiol, July 1, 2002; 283(1): G133 - G138. [Abstract] [Full Text] [PDF]

				H. Shen, D. E. Smith, T. Yang, Y. G. Huang, J. B. Schnermann, and F. C. Brosius III Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney Am J Physiol Renal Physiol, May 1, 1999; 276(5): F658 - F665. [Abstract] [Full Text] [PDF]

				H. Wang, Y.-J. Fei, V. Ganapathy, and F. H. Leibach Electrophysiological characteristics of the proton-coupled peptide transporter PEPT2 cloned from rat brain Am J Physiol Cell Physiol, October 1, 1998; 275(4): C967 - C975. [Abstract] [Full Text] [PDF]